Az Anthropic bemutatta a Life Sciences Verification Programot (LSVP), amely enyhébb biztonsági szűrőkkel enged utat a biológiai és orvosi kutatásoknak. A kezdeményezés célja, hogy a hitelesített szakemberek olyan feladatokra is használhassák a Mythos 5.1, az Opus 5 és a Sonnet 5 modelleket, amelyeket az általános verziók eddig blokkoltak. Ilyen terület például a gyógyszerfejlesztés, a klinikai kutatás és a gyártás támogatása.
A programban részt vevő csapatok 2 különböző engedélyt kaphatnak a háttérellenőrzés után. A Standard Use licenc a mindennapi kutatási feladatokhoz ad szabadabb kezet, míg a High-risk Use licenc minden biológiai korlátozást felold egy-egy konkrét, 6 hónapos projekt erejéig. A valós idejű blokkolás helyett az Anthropic utólagos, 30 napos adatmegőrzéssel járó monitorozással ellenőrzi a visszaéléseket.
Az LSVP jelenleg béta fázisban érhető el az API-n keresztül, valamint a Claude Enterprise és Team előfizetésekben. Az egyéni felhasználók számára egyelőre nem nyitották meg a lehetőséget, de az érdeklődő szervezetek már feliratkozhatnak a várólistára a fejlesztő oldalán.
Az eredeti szöveg (Anthropic)
Today, we are introducing the Life Sciences Verification Program (LSVP), which gives life science professionals access to our Mythos, Opus, and Sonnet models with a refined set of safeguards more permissive for biology-related work. We have already onboarded dozens of organizations through an early-access program, and are now opening applications to the broader life science community (join waitlist here). The program is launching in beta, initially for teams and institutions. We will continue to improve the program and expand access to individual Pro and Max plans over time.
The LSVP is designed to enable life science professionals to use our models across a wide range of tasks that are currently blocked in our generally available Fable models, like drug discovery, research biology, clinical development, and manufacturing. It’s built for teams of all kinds—from academic labs to startups, pharma companies, and more.
To qualify for these grants, each applicant goes through a verification process that includes a review of their research credentials, security standards, and ethical research oversight. Once verified, teams may apply for two types of LSVP grants, “Standard Use” or “High-risk Use,” depending on their access needs. These grants can be used through all our product surfaces, including Claude Science, Claude.ai, Claude Code and the API.Standard Use grants are suitable for most life science work, including the majority of biology research and development workflows. These grants can be extended to entire teams for diverse, daily workloads, and are renewed once a year. They give those teams access to our Mythos, Opus, and Sonnet models, with refined classifiers that are more permissive for science tasks than our generally available models. Standard Use grants apply to Mythos 5.1, Opus 5, and Sonnet 5 today, and to future models as they launch. They’re specifically designed to enable the full breadth of life science activities in areas spanning basic science, R&D, supply chain and manufacturing, clinical development, quality assurance, regulatory affairs, investing and diligence, and more.
Although we expect Standard Use to cover the majority of access needs, some work carries a higher potential for misuse and therefore requires additional vetting.
High-risk Use is an add-on grant for teams working in areas blocked under Standard Use. It removes all safeguards that block life sciences requests. This grant applies to a single research project as opposed to a full team, and must be renewed every six months. Typically, a single researcher with dual-use work would have access to one Standard Use grant for diverse, daily activities, and one or more High-risk Use grants which only apply to work on specific projects (for example, characterizing how one specific family of viral vectors is recognized by human immune pathways).
High-risk grants for Claude Opus 5 and Claude Sonnet 5 are available today. We are working with the US government to make high-risk grants more broadly available for Claude Mythos, but at the time of this launch they will remain limited to a small set of entities with additional vetting.
All other safeguards, such as cyber classifiers, will remain in place under LSVP grants.
As we’ve shown in our recent threat report, there are increasingly sophisticated misuse attempts happening on our platform, including attempts that could support biological weapons development. In biology, where it’s often not possible to differentiate between a user doing valid work (e.g. research a viral pathogen to develop vaccines against it) and pursuing harm (e.g. trying to increase the transmissibility of a virus maliciously), the most concerning threat models are ones where valid access has been diverted or overtaken by an actor with bad intent. Indeed, insider threats and rogue-use have been major factors in significant biosafety incidents and scares. In developing the LSVP’s safeguards, we aimed to protect against three con